# Mezagitamab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mezagitamab

> The next catalyst for mezagitamab, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mezagitamab |
| Codes | TAK-079 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Kidney Disease](https://sec-api.dev/indications/kidney-disease), [Antibody-Mediated Rejection (AMR)](https://sec-api.dev/indications/antibody-mediated-rejection-amr), [Immune Thrombocytopenic Purpura (ITP)](https://sec-api.dev/indications/immune-thrombocytopenic-purpura-itp) |
| Modality | antibody |
| FDA designations | fast track, orphan |

## Timeline

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immune Thrombocytopenic Purpura (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06722235 (A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06722235

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immune Thrombocytopenic Purpura (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06722235 (A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06722235

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06963827

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06963827

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Antibody-Mediated Rejection (AMR).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07613359 (A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-15 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07613359

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Antibody-Mediated Rejection (AMR).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07613359 (A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-15 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07613359

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immune Thrombocytopenic Purpura (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06948318 (A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06948318

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immune Thrombocytopenic Purpura (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06948318 (A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06948318

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mezagitamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mezagitamab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mezagitamab

```bibtex
@misc{secapidev_pdufa_mezagitamab_20261116,
  title        = {Mezagitamab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mezagitamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mezagitamab_20261116","title":"Mezagitamab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mezagitamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
